Friday, 25 May 2018

You are here

Trends in Psoriatic Arthritis Treatment 2004-2015

Lee and colleagues from Brigham and Women's Hospital have analyzed the last decade of disease‐modifying antirheumatic drugs (DMARDs) use in patients with psoriatic arthritis (PsA) and found nearly 40% were treated with a bDMARD, along with a decreasing trend in complete DMARD discontinuations.

Data claims were derived from a large US commercial health plan, and identified PsA patients initiating DMARD therapy and changes in the DMARD regimen over the next 12‐month period.

Among the 9,222 PsA patients who initiated DMARD therapy, 57% started with a conventional synthetic DMARDs [csDMARDs] and 43% began with a biologic DMARD [bDMARD].

Those starting on bDMARDs tended to be younger (48 yrs vs 52 yrs) and had fewer comorbidities.

Methotrexate was the most frequently used csDMARD (80.6%) and etanercept (49.1%) was the most commonly prescribed bDMARD, followed by adalimumab (34.4%).

In the first 12‐months 20.1% of bDMARD initiators and 31.1% of csDMARD initiators had a change in their DMARD regimen.

Very few patients (5.3%) totally discontinued therapy, but the rates of discontinuation decreased over time (P < 0.001).

These data suggest that  the majority of PsA patients initiating DMARD therapy will remain on DMARD therapy for many years.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Ankylosing Spondylitis Women Show Less Durable Responses to TNF Inhibitors

A study from the Netherlands has shown that the long-term drug survival of TNF inhibitors differ between men and women, with women having a lower long-term retention rate compared to men. A single-center, retrospective study of 122 anklylosing spondylitis (AS) patients, analyzed the outcomes of those receiving either  etanercept, adalimumab, or infliximab between 2004 and 2014.

Nearly 40% were women and most AS patients received adalimumab (59.7%), compared to etanercept (28.9%) or infliximab (11.3%).

Targeting IL-17A: A Winner in PsA

Psoriatic arthritis patients with inadequate response to tumor necrosis factor (TNF) inhibitors had improvements in their arthritis and psoriasis when treated with the interleukin (IL)-17A blocker ixekizumab (Taltz), according to a phase III study presented here at the annual conference of the British Society for Rheumatology.

Comorbidities Undermine Clinical Outcomes in Psoriatic Arthritis

Analysis of data from the DANBIO registry of psoriatic arthritis patients treated with tumor necrosis factor inhibitor therapy shows that comorbidities were associated with higher baseline disease activity, shorter TNFi persistence, and reduced clinical response rates to TNFi.

Apremilast in DMARD-Naive Psoriatic Arthritis

Apremilast (Otezla) monotherapy was effective for psoriatic arthritis among patients who had not previously received disease-modifying anti-rheumatic drugs (DMARDs) or biologics, a phase III clinical trial funded by the drug's manufacturer found. 

Bone Marrow Edema Found in SI Joint of Athletes

New research shows that young elite athletes will not commonly manifest bone marrow edema in the SI joint following activity.

A study in Arthritis & Rheumatology  assessed for MRI findings commonly seen in patients with axial spondyloarthropathy (axial Spa). (Citation source: https://buff.ly/2DrlCgB)